Wiese, Michael - University of South Australia - School of Pharmacy and Medical Sciences

研究领域

I am interested in the clinical use of medicines, and my predominant teaching role is in the pharmacotherapeutics subjects of the 3rd year of the Undergraduate Pharmacy Program.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Hopkins, AM, Proudman, SM, Vitry, A, Cleland, LG & Wiese, MD 2016, 'Ten years of Publically Funded Biological Disease Modifying Antirheumatic Agents in Australia', Medical Journal of Australia, v. 204, no. 2, pp.64-68. Rowland, A, Dias, MM, Wiese, MD, Kichenadasse, G, McKinnon, RA, Karapetis, CS & Sorich, MJ 2016, 'Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours', European Journal of Cancer, v. 55, pp. 122-130. Wimmer, BC, Bell, JS, Fastbom, J, Wiese, MD & Johnell, K 2016, 'Medication regimen complexity and polypharmacy as factors associated with all-cause mortality in older people: a population-based cohort study', Annals of Pharmacotherapy, v. 50, no. 2, pp. 89-95. Wojciechowski, J, Wiese, MD, Proudman, SM, Foster, DJ & Upton, RN 2016, 'A model-based evaluation of single metrics for discriminating changes in rheumatoid arthritis disease activity', British Journal of Clinical Pharmacology, v. 81, no. 6, pp. 1046-1057. Hopkins, AM, Foster, D, Wiese, M & Upton, R 2015, 'Response to Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomide - Should Consideration Be Given to Cannalicular Efflux Transporters?', CPT: Pharmacometrics and Systems Pharmacology, v. 4, pp. 464. Hopkins, AM, Vitry, A I, O'Doherty, CE, Proudman, SM & Wiese, MD 2015, 'Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide', International Journal of Rheumatic Diseases, v. 11, no. 1, pp. 1-3. Hopkins, AM, Wiese, MD, Proudman, SM, O'Doherty, C, Foster, DJR & Upton, RN 2015, 'Semiphysiologically based pharmacokinetic model of leflunomide disposition in rheumatoid arthritis patients', CPT: Pharmacometrics & Systems Pharmacology. Hopkins, AM, Wiese, MD, Proudman, SM, O'Doherty, CE, Upton, RN & Foster, DJR 2015, 'Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis', British Journal of Clinical Pharmacology, v. 81, no. 1, pp. 113-123. Mohamed, H, Sorich, MJ, Kowalski, SR, McKinnon, RA, Proudman, SM, Cleland, L & Wiese, MD 2015, 'The role and utility of measuring red blood cell methotrexate polyglutamate concentrations in inflammatory arthropathies - A systematic review', European Journal of Clinical Pharmacology, v 71, no.4, pp. 411-423. Reeve, E, Wiese, MD & Mangoni, A 2015, 'Alterations in drug disposition in older adults', Expert Opinion on Drug Metabolism and Toxicology. Rowland, A, Dias, MM, Wiese, MD, Kichenadasse, G, McKinnon, R, Karapetis, CS & Sorich, MJ 2015, 'Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer', British Journal of Cancer. Rowland, A, Dias, MM, Wiese, MD, Kichenadasse, G, Mckinnon, RA, Karapetis, CS & Sorich, MJ 2015, 'Reply: Comment on `Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'', British Journal of Cancer, v. 113, pp. 1635. Sorich, MJ, Wiese, MD, Rowland, A, Kichenadasse, G, McKinnon, R & Karapetis, CS 2015, 'Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized, controlled trails', Annals of Oncology. Wabe, N, Sorich, M, Wechalekar, M, Cleland, L, McWilliams, L, Lee, A, Spargo, L, Metcalf, R, Hall, C, Proudman, S & Wiese, M 2015, 'Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years', Arthritis Research and Therapy, v .17, pp. 1-14. Wanandy, T, Gueven, N, Davies, N, Brown, S & Wiese, MD 2015, 'Pilosulins: A review of the structure and mode of action of venom peptides from an Australian ant Myrmecia pilosula', Toxicon. Wimmer, B, Johnell, K, Fastbom, J, Wiese, MD & Bell, JS 2015, 'Factors associated with medication regimen complexity in older people: a cross-sectional population-based study', European Journal of Clinical Pharmacology, v. 71, no. 9, pp. 1099-1108. Wojciechowski, J, Wiese, MD, Proudman, SM, Foster, DJR & Upton, RN 2015, 'A Population Model of Early Rheumatoid Arthritis Disease Activity during treatment with Methotrexate, Sulfasalazine and Hydroxychloroquine', British Journal of Clinical Pharmacology, in press. Hopkins, AM, King, CE, Foster, DJR, Suppiah, V, Upton, RN, Spargo, L, Cleland, L, Proudman, SM & Wiese, MD 2014, 'The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity', Journal of Clinical Pharmacy and Therapeutics, v. 39, no. 5, pp. 555-560. Hopkins, AM, O'Doherty, CE, Foster, DJR, Upton, RN, Proudman, SM & Wiese, MD 2014, 'Individualization of leflunomide dosing in rheumatoid arthritis patients', Personalized medicine, v. 11, no. 4, pp. 449-461. Reeve, E & Wiese, MD 2014, 'Benefits of deprescribing on patients' adherence to medications', International Journal of Clinical Pharmacy, v. 36, no. 1, pp. 26-29.